Senolytics Guide for Longevity: Dasatinib Plus Quercetin, Fisetin, and Practical Risk Management

Senolytics are the most overclaimed category in consumer longevity. The pitch is clean: aging tissue accumulates senescent cells, senescent cells secrete inflammatory signals, so clearing them should restore function. The mechanism is real and the mouse data are genuinely interesting. The human data are thin enough that anyone selling you a finished protocol is selling ahead of the evidence. This guide is for readers who have already built the boring foundation, who understand that dasatinib is a chemotherapy drug, and who want to know precisely where the science stops rather than where the marketing starts. If you are looking for a dosing schedule to run on yourself, this article will not give you one.

Here is the scale you are working with. The largest published trial of dasatinib plus quercetin randomized 60 postmenopausal women. The three earlier studies covered below enrolled 14, nine, and five participants. A separate single-blind pilot assigned twelve pulmonary fibrosis patients to the combination or placebo and was built to test feasibility and tolerability rather than efficacy; it met those endpoints, with 65 non-serious adverse events logged in the treated arm against 22 on placebo, plus one post-study serious event judged unrelated to treatment. That is essentially the published human record for the combination, and it is dominated by feasibility work and cellular biomarkers rather than outcomes. This is a reasonable early stage in drug development. It is not a basis for a consumer protocol, and the gap between those two things is where most senolytics content goes wrong.

What follows is the mechanism, what each human trial actually measured, what the over-the-counter compounds do and do not have behind them, the specific label risks of dasatinib, and the failure modes that show up repeatedly in this space. Nothing here is individualized medical direction. Dasatinib is prescription-only, and any decision involving it belongs to a physician who can review your labs, your other medications, and your bleeding risk before anything else happens.

Senescent cells are cells that have stopped dividing but refuse to die. They persist and secrete a mix of cytokines, chemokines, and proteases known as the senescence-associated secretory phenotype, which drives inflammation in the surrounding tissue. They survive by upregulating pro-survival pathways that keep them out of apoptosis. Dasatinib and quercetin were paired because they interfere with different arms of that survival network, and because neither cleared senescent cells broadly on its own. Fisetin was identified later by screening flavonoids for the same activity. This is the entire theoretical basis: disable the survival machinery briefly, let the cells die, then stop dosing.

The animal data are the strongest part of the case. Mice given intermittent dasatinib plus quercetin starting late in life, well past the rodent equivalent of middle age, lived longer after treatment than vehicle controls, and transplanting small numbers of senescent cells into younger mice was enough to cause lasting physical dysfunction, which supports the causal direction rather than mere correlation. That is a coherent chain in rodents, and it is why credible labs are running human trials at all. Rodent lifespan results have failed to translate to humans repeatedly, including for compounds with far more human exposure than these have.

The boundary is sharp. Everything above is mechanism and animal work. In humans, the one randomized trial with an efficacy primary endpoint missed it, and no trial has reported a clinical outcome benefit: no reduced fracture rate, no reduced disease incidence, no survival difference. There is no human lifespan data and no long-term safety data for repeated intermittent dosing in people without cancer. If that surprises you, you have been reading product copy rather than trial reports. Our Rapamycin for Longevity: What the 2026 Evidence Actually Shows review lands in a similar place for similar reasons.

Start with the strongest study, because it is the one most product pages skip. In 2024 a Mayo Clinic group published a phase 2 randomized trial in Nature Medicine: 60 postmenopausal women aged 62 to 88, assigned to a control arm or to intermittent dasatinib 100 mg for two consecutive days plus quercetin 1,000 mg for three consecutive days, repeated every 28 days across 20 weeks. The primary endpoint was percentage change in the bone resorption marker CTx at 20 weeks. It missed. The treated group changed by a median of negative 4.1 percent against negative 7.7 percent in controls, a difference that was not statistically significant.

The secondary and exploratory findings are where the real signal might be, and also where overreading starts. The bone formation marker P1NP rose about 16 percent in the treated group at two and four weeks, then the difference disappeared by 20 weeks. In an exploratory subgroup of women in the highest tertile for T cell p16 messenger RNA, a proxy for senescent cell burden, P1NP rose 34 percent at two weeks and distal radius bone density rose 2.7 percent at 20 weeks. That is a hypothesis worth testing, not a result to act on. The trial was open-label rather than blinded because blinding was cost-prohibitive. No serious adverse events occurred; headache was reported by roughly half the treated group.

The first-in-human study came earlier, published in eBioMedicine in 2019. Fourteen patients with stable idiopathic pulmonary fibrosis took dasatinib 100 mg per day plus quercetin 1,250 mg per day for three consecutive days a week over three weeks, nine dosing days in total. It was open-label with no control arm. Six-minute walk distance improved by about 21.5 meters. Lung function measures, FEV1 and FVC, did not change. Adverse events were common: 68 events across the cohort, most often respiratory symptoms, skin irritation or bruising, and gastrointestinal discomfort. One participant was hospitalized after the intervention with pneumonia and pulmonary edema, which resolved.

A companion study gave nine people with diabetic kidney disease dasatinib 100 mg daily plus quercetin 500 mg twice daily for three days. Eleven days later, fat biopsies showed roughly 35 percent fewer p16INK4A-positive cells, 62 percent fewer cells with senescence-associated beta-galactosidase activity, and 86 percent fewer crown-like structures. Several plasma cytokines and matrix metalloproteinases were lower. No clinical outcome was measured at all. One detail worth carrying: the journal published a corrigendum in 2020 stating that a re-analysis of the raw data changed some of the paper's conclusions. That footnote rarely survives the trip into supplement marketing copy.

The 2023 phase 1 feasibility trial in mild Alzheimer's disease enrolled five people over twelve weeks, dosed on two consecutive days in each of six two-week cycles. Its most useful output was pharmacokinetic. Dasatinib reached cerebrospinal fluid in four of five participants, at under one percent of the plasma concentration. Quercetin was not detectable in cerebrospinal fluid at all, which matters if you are hoping a senolytic will act on brain tissue. Global cognitive scores and brain volumes on MRI did not change, though one memory subtest, Hopkins Verbal Learning Test-Revised immediate recall, declined significantly. The authors framed the overall pattern as supporting safety rather than efficacy. With five participants and no control group, no efficacy conclusion was available in either direction, and a single moving subtest is exactly what that design produces by chance.

Fisetin is the compound most people actually buy, because it is sold as a supplement while dasatinib is not. Its senolytic case rests on a 2018 mouse study in which fisetin fed to wild-type mice starting at 85 weeks of age, roughly a 75-year-old human, extended both median and maximum lifespan. The human component of that same paper was performed outside the body: omental fat removed during surgery and treated in culture. No living person received fisetin in that study. The distinction between tissue in a dish and a person swallowing capsules is the entire distinction, and product pages routinely collapse it.

The registered human trial to watch is AFFIRM-LITE, a phase 2 randomized, double-blind, placebo-controlled study of fisetin at 20 mg per kilogram per day for two consecutive days in older adults with frailty, run by Mayo Clinic with an estimated enrollment of 40. It started in November 2018. As of the most recent record update it is still enrolling by invitation, with estimated primary completion in November 2026 and no results posted. A 40-person phase 2 study has now been running for nearly eight years without a published result. That is the honest current state of fisetin in humans.

Practical consequences follow. Twenty milligrams per kilogram is 1,600 mg for an 80 kg adult, well above the per-capsule dose on most retail labels, and fisetin has low and variable oral absorption, so the delivered dose is uncertain even when the label is accurate. Quercetin has the same absorption problem and has never been tested alone as a senolytic in these trials; it was always the partner compound. Any product marketed as a complete senolytic stack because it contains quercetin and fisetin is describing an intervention nobody has studied. The evidence tiering in our Does Spermidine Work for Longevity? What the 2025 Human Trials Actually Show guide follows the same logic.

There is no validated blood test for senescent cell burden that you can buy. The reductions reported in the human trials came from fat and skin biopsies stained for p16INK4A, p21CIP1, and senescence-associated beta-galactosidase. The bone trial used p16 messenger RNA measured in isolated T cells. Those are research assays on excised tissue or sorted cells, not something a consumer lab offers. Any clinic selling a senescence score from a routine blood draw is selling a number with no established relationship to the measurements the trials actually used. Treat it as an unvalidated biomarker: interesting to look at, useless for making a decision.

What you can measure is function, which is what senolytics claim to protect anyway. Gait speed, grip strength, six-minute walk distance, VO2 max, and time to failure on a standardized aerobic test are reproducible and move with real interventions. On the blood side, hs-CRP, HbA1c, fasting insulin, and ApoB are cheap, standardized, and directly actionable. None of them is a senescence readout. They are the downstream outcomes you would want a senolytic to eventually improve, and our Longevity Biomarkers to Track: A Complete Measurement Guide guide covers testing cadence and interpretation for each of them.

Put those two facts together and the self-experiment framing collapses. You cannot measure the target, and the claimed effects are smaller than the week-to-week noise in any functional test you can run on yourself without a control group. An n-of-1 senolytic trial has no readout. It has a cost, a risk profile, and a feeling. Contrast that with training: raise your VO2 max and the number moves, reproducibly, in a direction backed by large prospective mortality data. Our VO2 Max Training for Longevity: High-Impact Programming Without Burnout covers how to move that number and how to confirm it moved.

Dasatinib is not a supplement. It is a prescription tyrosine kinase inhibitor approved in the United States only for Philadelphia chromosome-positive chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia. Its label carries warnings for myelosuppression, bleeding-related events, fluid retention including pleural effusion, cardiovascular toxicity, pulmonary arterial hypertension, QT prolongation, severe dermatologic reactions, tumor lysis syndrome, hepatotoxicity, and embryo-fetal toxicity. Those warnings were established under continuous daily dosing in cancer patients. Intermittent dosing has not been shown to eliminate them, and every trial above was far too small to detect an uncommon serious event.

The interaction list matters more than most readers expect. The label directs avoiding strong CYP3A4 inhibitors, with a dose reduction if coadministration is unavoidable. It states that H2 antagonists and proton pump inhibitors should not be given with dasatinib, and that antacids should be separated by at least two hours. It also warns that concomitant medications inhibiting platelet function, or anticoagulants, may increase the risk of hemorrhage. Read that last one against a typical longevity stack: low-dose aspirin, high-dose fish oil, and any direct oral anticoagulant all sit in that category. Strong CYP3A4 inhibitors include several common antifungal and macrolide antibiotic drugs.

Some people should not be anywhere near this. That includes anyone pregnant, breastfeeding, or trying to conceive; anyone taking an anticoagulant or antiplatelet drug; and anyone with a bleeding disorder, active infection, significant liver disease, known QT prolongation, or a history of pleural or pericardial effusion. It also includes anyone who would be obtaining dasatinib without a prescription, which is the single highest-risk decision in this category. Dasatinib is prescription-only, and sourcing an oncology drug from an unregulated seller adds identity and purity uncertainty on top of a real toxicity profile. If you are seriously considering this, the conversation belongs with a physician who can order a CBC, liver panel, and ECG first.

The first trap is the hit-and-run story, the claim that brief pulsed dosing is inherently safe because the drug clears quickly. Intermittent dosing was chosen because senescent cells do not repopulate within days, so continuous exposure is unnecessary. That is a pharmacological convenience argument, not a safety finding. The second trap is population transfer. Trial participants had pulmonary fibrosis, diabetic kidney disease, Alzheimer's disease, or postmenopausal bone loss. A metabolically healthy 45-year-old is a different population, and senescent cells also perform real work in wound healing and tumor suppression.

The third trap is the substitution stack: a product that borrows the trial language, drops the prescription drug, and sells quercetin plus fisetin plus a proprietary blend as though that combination were the thing studied. It was not. The fourth is treating anecdote as signal. Uncontrolled self-reports have no comparator and no blinding, and the most-quoted functional improvement in this literature is about 21.5 meters of six-minute walk distance in fourteen lung fibrosis patients with no control arm. The bone trial, which did have a comparator, missed its primary endpoint outright.

The fifth and most expensive trap is sequence error: spending attention and money on a frontier intervention while ApoB, blood pressure, cardiorespiratory fitness, muscle mass, and sleep sit unaddressed. Those five have either randomized outcome trials or very large prospective cohorts behind them. Senolytics have neither. If your blood pressure is untreated and you have not trained aerobically in a year, a senolytic protocol is not the constraint on your healthspan. Fix the ordering first; alivelongevity.com/protocol lays out the sequence in the order the evidence supports.

Here is the whole picture in tiers. Mouse lifespan extension with intermittent dasatinib plus quercetin: real, produced largely by overlapping research groups, and started at old age, which is the translationally relevant design. Human trials: one 60-person randomized phase 2 that missed its primary endpoint, plus a twelve-person randomized feasibility pilot and several small open-label studies. Human clinical outcome benefit: none reported. A commercially available, validated measure of your senescent cell burden: none exists. Regulatory status of dasatinib for aging: not approved anywhere for that use. Read every product page against those five lines.

A defensible position looks like this. Do not buy a senolytic stack expecting a clinical effect, because none has been demonstrated in humans. Do not source dasatinib off-label without a physician who understands its toxicity profile and can monitor for it. If the science genuinely interests you, look for a registered trial you qualify for rather than improvising at home. And keep frontier compounds in a clearly separate mental bucket from the interventions you already know work, so that budget and attention do not quietly leak from one to the other.

Three developments would change this assessment. First, a blinded trial with a functional primary endpoint such as gait speed or six-minute walk distance, in a general older population rather than a single disease group, that actually hits it. Second, a validated circulating marker of senescent cell burden, which would make both trials and personal tracking possible. Third, safety data on repeated intermittent dosing extending past a year in people without cancer. Until then, senolytics belong on your watch list, not in your cabinet. The same overclaiming pattern runs through our Stem Cell Therapy for Longevity in 2026: Overview, Claims, and Decision Guardrails review.